NovartI (nOVN) earnings Q4, full year FY24

Swiss drug giant Novartis Better sales than expected in the fourth quarter on Friday, but better sales in their leadership in full annual extension.

In the fourth quarter, the net sales increased by 16%, in LSEG in the survey of about $ 12,795 billion, up to $ 12,795 billion, 16%.

Quarterly adjustable basic operating revenues, reached $ 4.86 billion against $ 4.23 billion.

Net sales for 2024 rose to $ 50.32 billion for $ 50.32 billion on sustainable currency. Full annual basic operating revenues increased by 22% to $ 19.5 billion to $ 17.02 billion.

The company, primarily blockbuster card deficiency medication entestation and its arthritis medication cosents in the first place.

In October, in October, increased the leading of 2024 earnings for the third consecutive quarterly, increasing the ratio of “high teenagers in high teenagers” and major operating revenues are expected.

CEO Vas Narasimhan said the results hit a positive early signal due to the implementation of the business strategic repairs of the business in 2023.

“As an innovative drug company playing clean in the first year, Novartis is one of the strongest financial performances in our history, 12% CC (permanent currencies) and main operating income,” Narasimhan said the results of the statement.

“We are waiting for the rapid sales increase in the rapid margin of margin in 2025, and we remain on the way to convey our medium-term management.”

Narasimhan, who looked upon the upcoming Narasimhan, developed the development of the development pipeline, including more than 30 assets, was associated with the potential to develop with long-term growth potential.

The company also announced the leadership for 2025, forecasting net sales will increase “Medium-level figures” and the main operating income will increase to “high single digits”.